CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
This is the first update to the original CTS communication distributed on July 6th. As previously co...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...